Job descriptions

ESR1: Design, Synthesis and Biochemical evaluation of novel serine protease inhibitors

  • Host organisation: University of Antwerp (UA), Belgium
  • Duration: 36 months
  • Start date: June 2018
  • Planned industrial secondment: Mercachem, The Nederlands (3 months)
  • Planned academic secondment: LIOS, Latvia (3 months)

ESR2: Design, Synthesis and Biochemical evaluation of novel RIPK1 inhibitors

  • Host organisation: University of Antwerp (UA), Belgium
  • Duration: 36 months
  • Start date: June 2018
  • Planned industrial secondment: Mercachem, The Nederlands (3 months)
  • Planned academic secondment: UVA, Spain (3 months)

ESR3: Implementation of in vivo models to identify potential candidates for DED treatment

  • Host organisation: University of Antwerp (UA), Belgium
  • Duration: 36 months
  • Start date: June 2018
  • Planned industrial secondment: iBET, Portugal (3 months)
  • Planned academic secondment: UHC, Germany (3 months)

ESR4: Evaluation of the topic use of natural compounds for the treatment of ocular surface inflammatory diseases

  • Host organisation: University of Valladolid (UVA), Spain
  • Duration: 36 months
  • Start date: June 2018
  • Planned industrial secondment: iBET, Portugal (5 months)
  • Planned academic secondment: UHC, Germany (3 months)

ESR5: Upscaling of selected compounds from WP1 for formulation studies and in vivo evaluation

  • Host organisation: Latvian Institute of Organic Synthesis (LIOS), Latvia
  • Duration: 36 months
  • Start date: June 2018
  • Planned industrial secondment: Mercachem, The Nederlands (3 months)
  • Planned academic secondment: UA, Belgium (3 months)

ESR6: Development of new carriers to improve the bioavailability of topic formulations to treat ocular surface inflammatory diseases

  • Host organisation: University of Valladolid (UVA), Spain
  • Duration: 36 months
  • Start date: September 2018
  • Planned industrial secondment: HGBeyond Materials Science, Spain (4 months)
  • Planned academic secondment: UEF, Finland (2 months)

ESR7: Drug penetration to ocular surface tissues

  • Host organisation: University of Eastern Finland (UEF), Finland
  • Duration: 36 months
  • Start date: September 2018
  • Planned industrial secondment: HGBeyond Materials Science, Spain (3 months)
  • Planned academic secondment: UA, Belgium (2 months)

ESR8: Development of new biomarkers and imaging techniques for Dry Eye Disease

  • Host organisation: Sorbonne Université (SU), France
  • Duration: 36 months
  • Start date: June 2018
  • Planned industrial secondment: Horus Pharma, France (3 months)
  • Planned academic secondment: Centre d’Investigation Clinique (CHNO des Quinze-Vingts, INSERM), France (3 months)

ESR9: Cytokine and chemokine receptors and relationship to ocular pain

  • Host organisation: Sorbonne Université (SU), France
  • Duration: 36 months
  • Start date: June 2018
  • Planned industrial secondment: Horus Pharma, France (3 months)
  • Planned academic secondment: Centre d’Investigation Clinique (CHNO des Quinze-Vingts, INSERM), France (3 months)

ESR10: Anti-inflammatory dry eye therapy using a water-free delivery platform

  • Host organisation: University Hospital of Cologne (UHC), Germany
  • Duration: 36 months
  • Start date: June 2018
  • Planned industrial secondment: Novaliq, Germany (10 months)

ESR11: Development of novel diagnostic tools for dry-eye disease using optical coherence tomography (OCT)‚Äč

  • Host organisation: University Hospital of Cologne (UHC), Germany
  • Duration: 36 months
  • Start date: June 2018
  • Planned industrial secondment: Heidelberg Engineering, Germany (10 months)

ESR12: Extraction, recovery and regeneration of biopolymers from marine biomass and subsequent evaluation of biopolymers for new carrier formulation

  • Host organisation: The Institute of Experimental Biology and Technology (iBET), Portugal
  • Duration: 36 months
  • Start date: June 2018
  • Planned academic secondment: UVA, Spain (5 months)